Indaptus Therapeutics raises $24 million in private placement, revamps ATM agreement

Indaptus Therapeutics entered a Stock Purchase Agreement on September 8, 2026 to sell an aggregate of 20,338,974 shares of common stock in a private placement, for aggregate gross proceeds of approximately $24.0 million, before deducting offering expenses.¹

The company said it currently intends to use the net proceeds from the Private Placement for working capital, research and development and other general corporate purposes, which may include early-stage research and preclinical evaluation of a potential neurotechnology and neural-network-based device for certain sleep-related conditions, with a view toward a potential future FDA submission.¹

The per-share purchase price was set using a formula: the purchase price per Share equals the Nasdaq Minimum Price, plus $0.015 per Share, where the Nasdaq Minimum Price is the lower of the Nasdaq official closing price on the trading day before execution of the agreement or the average closing price over the five trading days before execution.¹ The deal's closing is subject to customary conditions, and the Purchase Agreement provides that the Closing will occur on the third business day following satisfaction or waiver of the applicable closing conditions, and in any event no later than the fifteenth business day following September 8, 2026.¹

Separately, on August 28, 2026, Indaptus entered into an Amended and Restated At the Market Offering Agreement with H.C. Wainwright & Co., LLC, which amends and restates in its entirety, and supersedes and replaces, the original At The Market Offering Agreement dated June 1, 2022.² Under the new agreement, the Company may issue and sell through or to Wainwright shares of Common Stock having an aggregate maximum offering price of up to $100,000,000.² Wainwright will earn a placement fee equal to 3.0% of the gross sales price of shares sold as sales agent.²

An 8-K/A dated September 4, 2026 stated it was filed solely to update the Original Form 8-K to reflect the Company's filing of Amendment No. 1 to the prospectus supplement dated August 31, 2026, which updates certain disclosure in the section entitled "Dilution."³